<DOC>
	<DOCNO>NCT00405340</DOCNO>
	<brief_summary>Membranous glomerulopathy ( MN ) still common glomerular disease associate nephrotic proteinuria ( NS ) . Up 40 % patient reach end stage renal failure ( ESRD ) , make MN 2nd 3rd common cause ESRD cause primary glomerulopathy . Current treatment option include corticosteroid , alkylating agent , cyclosporin , use controversial associate adverse effect high cost temper usage . Experimental data MN suggest B cell activation result immunoglobulin deposition along glomerular basement membrane cause injury membrane subsequent proteinuria . Drugs non-selectively inhibit B cell , pathogenic antibody , closely associate improved outcome . Based rationale selective depletion B cell human would prevent production ? nephrotoxic ? immunoglobulin subsequent renal injury recently treat 15 patient MN rituximab 1g i.v . twice ( day 1 day 15 ) . Baseline proteinuria 13.0±5.5g/24h decreased 9.1±7g , 9.7±8g 6.5±6 g/24h 3 , 6 , 9 month , respectively ( mean ± SD ) . Analysis pharmacokinetic data obtain study , however , suggest heavily nephrotic patient , rituximab dose fashion result patient under-treated . The present study propose test hypothesis rituximab , give accordance standard lymphoma protocol ( 375mg/m2 x 4 ) , result effective profound depletion B cell , complete suppression pathogenic antibody , high remission rate NS maintain favorable safety profile .</brief_summary>
	<brief_title>Rituximab Treatment Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description>. Study Overview : Once patient idiopathic MN proteinuria &gt; 5g/24h identify meet entry criterion , he/she receive minimum 4 month non-immunosuppressive therapy aim maximize Ang II blockade ( run-in phase ) . The target blood pressure ( &lt; 130 mmHg systolic BP &gt; 75 % reading ; &lt; 100 mmHg systolic ) chosen base recent recommendation JNC VII . ( 38 ) 1 ) The first step administration ARB . This chosen ARBs effective ACEIs block AT1 mediate adverse effect Ang II , well tolerate , minimal cough angioedema , less hyperkalemia . Because part study aim maximize Ang II blockade , ARB dose continue increase every 2 week maximum tolerated/FDA approve dose achieve intolerable side effect occur ( e.g . development postural hypotension , light head , hyperkalemia , etc ) . 2 ) Once ARB dose maximize observable side-effects , and/or blood pressure target , long act ACEi add . ACEi dose increase every 2 week aim achieve maximum tolerated maximum approve dosage . For patient whose blood pressure control target additional medication add follow order : 3 ) loop diuretic , 4 ) cardioselective &amp; # 946 ; -blocker , 5 ) non-dihydropyridine calcium channel blocker ( CCB ) , 6 ) clonidine . The selection drug adhere recommendation JNC VII . ( 38 ) The choice non-dihydropyridine CCB make concern dihydropyridine-type CCB may obscure anti-proteinuric effect therapy . In order ensure potential adverse effect minimize limited CCB use fifth agent , use combination ARB/ACEi , diuretic , &amp; # 946 ; -blocker fail reduce BP target level . Concomitant Treatment : 1 . At start run-in/conservative phase study , part standard care patient NS severe hyperlipidemia , patient start atorvastatin 10 mg day ( equivalent ) tolerate ( evidence persistent elevation liver transaminase &gt; 3x upper limit normal , muscle pain , high CK , rhabdomyolysis ) dose increase accord recently publish KDOQI-dyslipidemia guideline . ( 39 ) The dose increase maximum 40 mg/day . The rationale use high statin dose risk develop proteinuria use statins high dos . Patients remain high tolerate dose entire duration study . Serum lipid measure baseline every 3 month thereafter . 2 . High sodium intake ( e.g . &gt; 200 mm NaCl/d 4.6 g sodium/d ) significantly impair beneficial effect Ang II blockade . ( 40 ) Therefore patient instruct go low salt diet ( 2-3g/day ) . 3 . Patients receive dietary counseling enrollment regard dietary protein target intake 0.8 g/kg ideal body weight/day high quality protein encourage maintain diet throughout duration study . Rituximab : If end period patient still meet entry criterion he/she treat rituximab , 375 mg/m2 i.v . day 1 , 8 , 15 22 , subsequent follow-up least one year . Patients retreat month 6th B-cells return circulation independent clinical status patient . B-cell return define CD19+B cell count &gt; 15/microliter &gt; 5 % baseline count . There +/- 3 day window study visit , account weekend , holiday , schedule conflict . Figure 3 . Schematic time-line study . Primary endpoint . 1 . Change proteinuria baseline 12 month . This approach select take consideration B cell recovery follow administration rituximab usually begin 6 month last infusion , complete 9-12 month later , ( complete recovery define normalization CD19+ B cell count ; normal CD19+ count 71-567 cells/ &amp; # 956 ; l ) . Secondary endpoint . 1 . Complete partial remission rate 6 , 9 , 12 month ( see definition Table 3 ) 2 . Pharmacokinetics/bioavailability 3 . Rate decline urinary protein 4 . Frequency relapse CR 5 . Toxicity</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Idiopathic MN diagnostic biopsy perform within past 24 month . Age &gt; 18 year If female , must postmenopausal , surgically sterile practice medically approve method contraception Patients need treat ACEI and/or ARB , least 4 month prior rituximab treatment adequately control blood pressure ( BP &lt; 130/75 mm Hg &gt; 75 % reading ) . Proteinuria measure urinary proteinuria / urinary creatinine &gt; 5.0 spot sample aliquot 24hour urine collection . Estimated GFR &amp; # 8805 ; 30 ml/min/1.73m2 take ACEI/ARB therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>